Trovagene (NASDAQ: TROV), which started out as a diagnostics company, has renamed itself Cardiff Oncology to better reflect its focus on the cancer drug it is advancing in three clinical trials.

In 2017 the San Diego area-based biotech made the first step in its transformation into a drug development-focused organization, licensing rights to an investigational cancer drug from Italy’s Nerviano Medical Sciences. Now that drug, onvansertib, is being evaluated as a potential treatment—in combination with other drugs—for patients with colorectal cancer, acute myeloid leukemia, and prostate cancer.

Along with the name change, the company is getting a new chief executive. Mark… Read more »

UNDERWRITERS AND PARTNERS